- Home
- TCBP
as 11-15-2024 4:00pm EST
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
| Founded: | 2013 | Country: | United Kingdom |
| Employees: | N/A | City: | HOLYTOWN |
| Market Cap: | 3.0M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -164.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $138.00 | Next Earning Date: | 11-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest TC BioPharm (Holdings) plc News
TCBP Breaking Stock News: Dive into TCBP Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
PR Newswire
19 days ago
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
MT Newswires
24 days ago
TC BioPharm Rejects Delisting Rumors, Confirms Nasdaq Listing Compliance
PR Newswire
24 days ago
TCBP Responds to False Social Media Claim
PR Newswire
a month ago
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
PR Newswire
a month ago
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
PR Newswire
2 months ago
TCBP Announces Site Opening of Guys and St. Thomas Hospital
PR Newswire
2 months ago
TCBP to Present at the 2024 ThinkEquity Conference in NYC
Compare TCBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TCBP TC BioPharm (Holdings) plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.